SELZENTRY

Compare SELZENTRY  to:
Compare
Compare

Generic Name for SELZENTRY

Maraviroc 150mg, 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SELZENTRY

CCR5 co-receptor antagonist.

Manufacturer of SELZENTRY

Pfizer Labs

Indications for SELZENTRY

HIV-1 infection in treatment-experienced adults infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals.

Adult dose for SELZENTRY

Swallow whole. ≥16yrs: Concomitant CYP3A inhibitors (eg, PIs except tipranavir/ritonavir, delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin) (with or without a CYP3A inducer): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, NRTIs, enfuvirtide: 300mg twice daily. Concomitant CYP3A inducers (eg, efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) (without a strong CYP3A inhibitor): 600mg twice daily. Renal dysfunction (CrCl<50mL/min) and CYP3A inhibitors: monitor closely for side effects (eg, dizziness).

Children's dosing for SELZENTRY

<16yrs: not recommended.

Warnings/Precautions for SELZENTRY

Do tropism testing before starting therapy. Pre-existing liver dysfunction or co-infected with viral hepatitis B or C. Consider discontinuing therapy if hepatitis or elevated LFTs with rash or other systemic symptoms develop. Cardiovascular risk factors. Postural hypotension. Monitor for immune reconstitution syndrome, infections, malignancies. Pregnancy (Cat. B). Nursing mothers: not recommended.

Interactions for SELZENTRY

Concomitant St. John's wort: not recommended. May affect, or be affected by, CYP3A inhibitors or inducers and drugs affected by p-glycoprotein (eg, potentiated by ketoconazole, lopinavir/ritonavir, ritonavir, saquinavir, atazanavir; antagonized by rifampin, efavirenz). Caution with antihypertensives.

Adverse Reactions for SELZENTRY

Upper respiratory tract infections, cough, pyrexia, upper respiratory infections, rash, musculoskeletal symptoms, constipation, dizziness; hepatotoxicity (may be preceded by systemic allergic reaction; immediately evaluate if occurs); others (see literature).

How is SELZENTRY supplied?

Tabs—60

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions